FDA 483 - Aurobindo Pharma USA Inc - June 15, 2024

The provided document content is incomplete, consisting solely of page number references without the actual text of the FDA 483 inspection report. Consequently, essential details such as the company name, specific inspection dates, identified violations or issues, the applicable regulatory framework, and any required corrective actions cannot be extracted or summarized. To provide a comprehensive and accurate summary as requested, the complete content of the FDA 483 document is necessary.